Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma.

Phase 1

Terminated

• Conditions: Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia; B-cell Precursor Acute Lymphoblastic Leukaemia; T-cell Non-Hodgkin's Lymphoma

• Registration Number: NCT00742495
• Lead Sponsor: Mundipharma Research Limited

Brief Summary

The purpose of this study is to evaluate the pharmacokinetics, pharmacodynamics and safety of different doses of intravenous and oral Forodesine in children with relapsed or refractory T-cell or B-cell precursor Acute Lymphoblastic Leukaemia or T-cell Non-Hodgkin's Lymphoma. Preliminary efficacy will also be assessed.

Detailed Description

A multi-centre, multi-national, open label trial of Forodesine in children with relapsed or refractory T-cell or B-cell precursor Acute Lymphoblastic Leukaemia or T-cell Non-Hodgkin's Lymphoma. The primary objective of the study is to evaluate the pharmacokinetics and pharmacodynamics of six different dose schedules of Forodesine. Secondary objectives are to evaluate safety and to collect preliminary efficacy data. All patients will receive active drug. The Initial Treatment Phase will last 37 days with a final response assessment on Day 37. Patients who achieve a response may be eligible to receive extended treatment with Forodesine for up to 6 months.

Study Timeline

• Study First Submitted: 2008-08-26
• Study First Submitted QC: 2008-08-26
• Study First Posted: 2008-08-27
• Study Start: 2009-03
• Primary Completion: 2010-09
• Study Completion: 2010-09
• Status Verified: 2012-02
• Last Update Submitted: 2012-10-23
• Last Update Posted: 2012-10-24

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 2

Inclusion Criteria

• Males and females aged ≥ 2 years to ≤18 years. ≥ 13 kg
• Female subjects of childbearing potential (i.e. have reached the age of menarche) must have a negative serum or urine pregnancy test recorded prior to the first dose of study medication, be non-lactating, and be willing to use adequate and highly effective method of contraception throughout the study and for one month after the last dose of study medication, if sexually active.
• Sexually active male subjects must be willing and able to use a barrier form of contraception (i.e. condoms) or sexual abstinence throughout the study and for one month after the last dose of study medication
• Unequivocal histological diagnosis of T-ALL, BCP-ALL or T-NHL (World Health Organisation [WHO] classification) at initial diagnosis
• Relapse (³25% marrow blasts) or failure to respond after at least one standard regimen for their disease for subjects with a T-cell malignancy who are ineligible for other therapy of greater curative potential, or failure to respond after at least two standard regimens for subjects with a B-cell precursor malignancy
• KPS or LPS (as appropriate for subject's age) scores ³60
• Anticipated life expectancy of at least 6 weeks
• Adequate kidney (creatinine levels ≤ 2.0 times upper limit of normal) and liver function tests (aspartate aminotransferase [AST] and/or alanine aminotransferase [ALT] ≤3 times upper limit of normal and total bilirubin ≤5 times upper limit of normal)
• Signed ICF and assent if appropriate according to local laws and regulations prior to start of any study specific procedures.

Exclusion criteria:

• Females who are pregnant (positive β-hCG test) or lactating
• Subjects with a history of HIV and/or HTLV-1
• Subjects with known active HBV, HCV, CMV and/or EBV infection
• Subjects with clinical evidence of active symptomatic CNS disease
• Subjects with active serious infection
• Prior treatment with any antileukemic agent, chemotherapy or leukophoresis treatment within 7 days (within 4-5 days for 6-mercaptopurine (MP) and within 2 days for low-dose methotrexate) prior to study entry
• Lack of full recovery from adverse drug reactions due to prior therapy, independent of when that therapy was given
• Concurrent treatment with other anticancer agents (CNS prophylaxis e.g. intrathecal methotrexate and corticosteroid use will not be excluded)
• Subjects who have chronic gastrointestinal disease or conditions that may hamper compliance and/or absorption of the product; however, study drug administration via nasogastric or gastrostomy tube is allowed
• Any history of hypersensitivity or intolerance to any component of the study medication.
• Subjects who have received an investigational medicinal product within 30 days of study entry (defined as the start of the Screening Period).
• Current participation in another clinical trial is not permitted unless the sole purpose of the trial is for long term follow up/survival data.

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Pharmacokinetics and pharmacodynamics - data will be collected on Day 1, 5, 8 and 36.	Day 1, and 36

Secondary Outcome Measures

Name	Time	Method
Safety data will be collected throughout the study. Efficacy will be assessed on Day 15 and Day 37.	Day 15 and 37

Trial Locations

Locations (4)

Prof Gerard Michel; 🇫🇷 Marseilles, France

Charite Universitymedicine; 🇩🇪 Berlin, Germany

Dr Giovanna Gioriani; 🇮🇹 Pavia, Italy

Sally Kinsey; 🇬🇧 Leeds, United Kingdom